In addition to indication benchmarks based on 18 years of historical drug development data, GlobalData also tracks the likelihood of phase change and approval scores for specific drugs. The attributes of the drug, the company, and its clinical trials play an important role in drug-specific PTSR and likelihood of approval.
APG-1387 is being developed to treat advanced solid tumors, including nasopharyngeal cancer, advanced pancreatic ductal adenocarcinoma, advanced non-small cell lung cancer, colorectal cancer, blood cancers, pancreatic cancer, peritoneal carcinomatosis (peritoneal cancer) and hepatitis B. It is being developed to treat head and neck cancers, leukemias and lymphomas. The drug candidate is a new chemical entity that is administered via intravenous and parenteral routes. The drug candidate works by targeting inhibitors of apoptosis proteins (IAPs).
Ascentage Pharma (Ascentage) is a biotechnology company dedicated to the discovery and development of targeted small molecule therapies for the treatment of cancer, hepatitis B and age-related diseases. It develops therapies that inhibit protein-protein interactions to restore apoptosis, or programmed cell death. The company’s product lines include HQP8361, APG-2449, APG-2575, APG-1252, APG-115, APG-1387, APG-5918, APG-265, AS1266 and UBX1967/1325. Ascentage Pharma’s lead product candidate, HQP8361, is a second-generation c-Met kinase inhibitor for the treatment of c-Met-positive cancers, gastric cancer, non-small cell lung cancer and liver cancer. The company has R&D centers and production facilities in Hong Kong, China and the United States. Ascentage Pharmaceuticals is headquartered in Suzhou, Jiangsu, China.
For complete information on APG-1387 drug-specific PTSR and LoA scores, purchase the report here.
Desde
GlobalData’s unparalleled proprietary data combines expertise with cutting-edge technology, allowing you to decipher what’s happening in the market. You can make smarter decisions and gain a future-proof advantage over your competitors.
Editors Bethesda Softworks Developers Bethesda Softworks Release date nineteen ninety six Gender Role playing game…
Editors Knowledge adventure Developers Knowledge adventure Release date 1999 Gender Educational Game Rating Game Description…
Editors Activision Developers Activision Release date nineteen ninety six Gender Simulation Game Rating Game Description…
Editors Interplay Productions Inc Developers Interplay Productions Inc Release date 1992 Gender Strategy Game Rating…
Editors The learning company Developers The learning company Release date 1997 Gender Educational Game Rating…
Editors SEGA Enterprises Ltd. Developers Sega AM7 R&D Division, System Sacom Release date 1998 Gender…